Dupilumab Shows Sustained Disease Control in Pediatric Atopic Dermatitis Cohort

A multicenter prospective BioDay Registry cohort assessed dupilumab effectiveness, safety, and treatment persistence in 309 patients aged 16 years or younger with moderate to severe atopic dermatitis. Patients received label-recommended dosing at seven Dutch hospitals, with dose reduction when clinically indicated. Outcomes included Eczema Area and Severity Index (EASI), Investigator Global Assessment, itch, pain, quality of life, adverse events, and discontinuation.

At three years, mean EASI was 3.4 (95% CI, 2.4–4.5), and mean pruritus Numeric Rating Scale score was 3.6 (95% CI, 3.1–4.1). Children aged six months to five years had higher itch scores and greater quality-of-life impairment than older children. Dupilumab-associated ocular surface disease was the most frequently reported adverse event, affecting 113 patients (36.6%).

Overall, 50 patients (16.2%) discontinued treatment, mainly because of ineffectiveness (19), adverse events (15), and/or administration problems (11). Most discontinuations occurred within 1.5 years; estimated three-year treatment persistence was 80.1%. Allergic asthma, allergic rhinitis, and age six to 11 years were associated with lower discontinuation risk.

These findings support sustained disease control in routine pediatric care while highlighting ocular adverse events and age-specific administration challenges. However, this observational cohort had no comparator described, and median follow-up varied from 45 weeks in the youngest group to 89.5 weeks in adolescents. The supplied abstract does not report how many patients contributed three-year outcome data.